Literature DB >> 32615101

Has dose-dense chemotherapy met an ICONic end?

Emily M Hinchcliff1, Larissa A Meyer1, Shannon N Westin2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32615101      PMCID： PMC8284846          DOI： 10.1016/S1470-2045(20)30276-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016).

Authors:  K Harano; F Terauchi; N Katsumata; F Takahashi; M Yasuda; S Takakura; M Takano; Y Yamamoto; T Sugiyama
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

3.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

Authors:  Sandro Pignata; Giovanni Scambia; Dionyssios Katsaros; Ciro Gallo; Eric Pujade-Lauraine; Sabino De Placido; Alessandra Bologna; Beatrice Weber; Francesco Raspagliesi; Pierluigi Benedetti Panici; Gennaro Cormio; Roberto Sorio; Maria Giovanna Cavazzini; Gabriella Ferrandina; Enrico Breda; Viviana Murgia; Cosimo Sacco; Saverio Cinieri; Vanda Salutari; Caterina Ricci; Carmela Pisano; Stefano Greggi; Rossella Lauria; Domenica Lorusso; Claudia Marchetti; Luigi Selvaggi; Simona Signoriello; Maria Carmela Piccirillo; Massimo Di Maio; Francesco Perrone
Journal:  Lancet Oncol       Date:  2014-02-28       Impact factor: 41.316

4.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

5.  Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Authors:  John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

6.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Seiji Isonishi; Fumiaki Takahashi; Hirofumi Michimae; Eizo Kimura; Daisuke Aoki; Toshiko Jobo; Shoji Kodama; Fumitoshi Terauchi; Toru Sugiyama; Kazunori Ochiai
Journal:  Lancet Oncol       Date:  2013-08-13       Impact factor: 41.316

7.  Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.

Authors:  Andrew R Clamp; Elizabeth C James; Iain A McNeish; Andrew Dean; Jae-Weon Kim; Dearbhaile M O'Donnell; Jane Hook; Christopher Coyle; Sarah Blagden; James D Brenton; Raj Naik; Tim Perren; Sudha Sundar; Adrian D Cook; Gosala S Gopalakrishnan; Hani Gabra; Rosemary Lord; Graham Dark; Helena M Earl; Marcia Hall; Susana Banerjee; Rosalind M Glasspool; Rachel Jones; Sarah Williams; Ann Marie Swart; Sally Stenning; Mahesh Parmar; Richard Kaplan; Jonathan A Ledermann
Journal:  Lancet       Date:  2019-11-29       Impact factor: 79.321
  7 in total
  1 in total

1.  Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The "Finer Points".

Authors:  Franco Muggia
Journal:  Oncologist       Date:  2020-11-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.